The injectable treatment showed a 30-percentage-point advantage over placebo in submental fat responder rates after a single treatment cycle, supporting plans for a regulatory filing in China by year-end.
The injectable treatment showed a 30-percentage-point advantage over placebo in submental fat responder rates after a single treatment cycle, supporting plans for a regulatory filing in China by year-end.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The injectable treatment showed a 30-percentage-point advantage over placebo in submental fat responder rates after a single treatment cycle, supporting plans for a regulatory filing in China by year-end.
Open the app view to save this story, compare related coverage, and continue from the same source.